CClinicalTrials.gg
CompletedNCT05993130Updated Aug 15, 2023

Evaluation of Patients With Covid-19 Infection in Terms of Severity of Osteoprosis

An observational study in Severity of Osteoprosis, sponsored by Kayseri Education and Research Hospital. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by Kayseri Education and Research Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
55
Ages
18 Years to 100 Years
Sex
Female
01

Study summary

Osteoporosis is a condition characterized by decreased bone strength and an increased risk of fracture. Age, gender, body mass index, fragility fracture history, corticosteroid use, immobilization, smoking and alcohol use, endocrine pathologies besides inflammatory and infectious pathologies can also be effective in the development of osteoporosis. The aim of the study is to evaluate the effect of Covid-19 infection on the development of osteoporosis.

In this study, bone mineral density (BMD) measurements of patients with Covid-19 infection were examined. For this, dual-energy x-ray absorptiometry (DEXA) measurement was used. A total of 55 patients were included in the study and data such as age, height, weight, comorbidities, drugs used, and treatment methods were recorded. Results showed that the time spent in the intensive care unit was associated with the femoral neck T score in DEXA measurements of patients with Covid-19 infection. The use of drugs such as alendronate, zolendronate, denosumab or teriparatide during the treatment process did not have a statistically significant effect on the lumbar and femur T scores.

02

Conditions studied

  • Severity of Osteoprosis
03

In context

Lead sponsor

Kayseri Education and Research Hospital is the lead sponsor of 26 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Between August 2020 and July 2021, two separate excel files were created for the identification numbers of the patients who had DEXA measurements and the identification numbers of the patients who had covid. Then, common ID numbers were found in both excel files in the computer environment. Among these patients, female patients over the age of 18 who had dexa measurements twice before and after covid, with at least one year between two dexa measurements and at least one month after covid infection were included in the study.

Inclusion criteria

  • Female patients over the age of 18 who had dexa measurements twice before and after covid, with at least one year between two dexa measurements, and at least one month after covid infection were included in the study.

Exclusion criteria

Exclusion Criteria:

  • Under the age of 18, male patients, patients with a diagnosis other than Covid-19 infection that will affect bone metabolism between the two dexa shooting dates before and after covid, patients who use another drug other than covid treatment that will affect bone metabolism between the two dexa shooting dates before and after covid not included in the study
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
55 participants (actual)
Patient registry
No

Interventions

  • OtherThe patients were not intervened. This is a retrospective study

    The patients were not intervened. This is a retrospective study

06

What researchers measure

Primary outcomes

  1. Does the severity of osteoporosis increase in patients with Covid-19 infection?

    Time frame: 2020 August 2021 July

07

Study locations

1 site
  • Kayseri City Hospital
    Kayseri, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05993130
Lead sponsor
Kayseri Education and Research Hospital
Responsible party
Dr. Ayşe Güç (physical medicine and rehabilitation, Kayseri Education and Research Hospital) — Principal investigator
First posted
Aug 15, 2023
Start date
Jan 15, 2021
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022
Last update
Aug 15, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion